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Objectives
To analyze RA patients treated with biologics in a Uni-
versity Hospital. Proportion of patients treated with dif-
ferent drugs, as first, second or third choice. To know
the disease activity before and after biologic therapy. To
know side effects and the reasons.
Material and methods
We have reviewed all RA patients treated with biologicals
from 1998 to January 2010. We include all patients with
at least 6 months of follow up and analyze clinical effi-
cacy as improvement in DAS count. We registered the
cause for switch among biologic drugs and the response
to a new biologic. Our hospital attends about 350.000
inhabitants and the prevalence of RA in Spain, as settled
by Spanish Society for Rheumatology is 0.5%, so we
could expect to have about 1800 RA patients, so we are
treating about 12% of RA patients with biologicals.
Results
We have reviewed 206 patients, 68% female, mean age
56.5, average duration of the disease 10.8 years. RF positive
79.3% CCP 68.2%, erosive 58.2%. Initial DAS was 5.8 and
at the end evaluation 53,6% of patients have a DAS<2.6.
Etanercept was the most used at onset (58%), 76 patients
(36.4%) switched for inefficacy (62%) or side effects
(21.7%).
Side effects were registered in 39%, with drug stop in
81% and hospital admission in 18.9%. The more com-
mon side effects were reactions at the injection site 33%,
infectious processes 23.1% and skin alterations 17.9%.
Conclusions
The disease activity was high when biologic started,
(DAS 5.8). The main cause of switching is loss of effi-
cacy. Etanercept is the more prescribed drug to initiate
biologic therapy.
Rituximab and Etanercept are used as a second option
in the majority of patients. Abatacept is used only after a
second switch. The improvement of patients is notorious
with RA remission by DAS<2.6 in 53,6% of patients. The
frequency of switch biologics is similar to other registry
experiences.
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